Davis's Drug Guide
ribociclib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
rye-boe-sye-klib
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Kisqali
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Ribociclib." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110459/6/ribociclib.
Vallerand AHA, Sanoski CAC. Ribociclib. Davis's Drug Guide. F.A. Davis Company; 2026. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110459/6/ribociclib. Accessed June 26, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Ribociclib. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110459/6/ribociclib
Vallerand AHA, Sanoski CAC. Ribociclib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 26]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110459/6/ribociclib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ribociclib
ID - 110459
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://www.unboundmedicine.com/washingtonmanual/view/Davis-Drug-Guide/110459/6/ribociclib
PB - F.A. Davis Company
ET - 20
DB - The Washington Manual
DP - Unbound Medicine
ER -
